Zydus Wellness Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
ZYDUSWELL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.1 pts less than Nifty Smallcap 250 and 0.5 pts more than its Packaged Foods peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Zydus Wellness' board approved audited standalone and consolidated results for Q4 and FY25 on May 19, 2025, with auditors Mukesh M. Shah & Co. issuing an unmodified (clean) opinion. On a consolidated basis, revenue from operations grew about 16% to ₹27,089 million (FY24: ₹23,278 million), while net profit jumped around 30% to ₹3,469 million (FY24: ₹2,669 million), aided by a ₹59 million exceptional gain from the sale of the 'Equals Two' brand. The company completed the acquisition of Naturell (India) Private Limited on December 2, 2024 for ₹3,690 million upfront, which contributed to the full-year numbers. Standalone results were weaker, with revenue at ₹2,926 million but net profit falling to ₹306 million (FY24: ₹337 million). The board recommended a final dividend of ₹6 per share (60%) and approved a stock split from face value of ₹10 to ₹2, subject to shareholder approval.
Consolidated earnings beat prior year on both revenue and profit, supported by the Naturell acquisition and brand divestiture gains, which should be viewed positively by investors. The proposed dividend and 5:1 stock split are shareholder-friendly and could improve retail participation and liquidity. Standalone weakness is a point to watch, but overall the clean audit opinion and strong consolidated growth are reassuring signals.